Protein kinase C as a tumor suppressor

Seminars in Cancer Biology

Volumn 48, Issue , 2018, Pages 18-26

  Newton, Alexandra C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diacylglycerol; LOF; Phorbol esters; PKC; Tumor suppressor

Indexed keywords

ONCOPROTEIN; PHORBOL ESTER; PROTEIN KINASE C; ISOENZYME;

ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SUBSTRATE; GERMLINE MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; TUMOR PROMOTION; GENETICS; METABOLISM; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ENZYME ACTIVATION; GENES, TUMOR SUPPRESSOR; HUMANS; ISOENZYMES; MUTATION; NEOPLASMS; PHORBOL ESTERS; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 85019848011     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.04.017     Document Type: Review

References (126)

1. Takai, Y., et al. Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. Biochem. Biophys. Res. Comm. 91 (1979), 1218–1224.
2. Hokin, M.R., Hokin, L.E., Enzyme secretion and the incorporation of P32 into phospholipids of pancreas slices. J. Biol. Chem. 203 (1953), 967–977.
3. Carrasco, S., Merida, I., Diacylglycerol, when simplicity becomes complex. Trends Biochem. Sci. 32:1 (2007), 27–36.
4. Manning, G., et al. The protein kinase complement of the human genome. Science 298:5600 (2002), 1912–1934.
5. Levin, D.E., et al. A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle. Cell 62 (1990), 213–224.
6. Watanabe, M., Chen, C.-Y., Levin, D.E., Saccharomyces cerivisiae PKC1 encodes a protein kinase C (PKC) homolog with a substrate specificity similar to that of mammalian PKC. J. Biol. Chem. 269 (1994), 16829–16836.
7. Newton, A.C., Protein kinase C: poised to signal. Am. J. Physiol. Endocrinol. Metab. 298:3 (2010), E395–402.
8. Dries, D.R., Gallegos, L.L., Newton, A.C., A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J. Biol. Chem. 282:2 (2007), 826–830.
9. Kazanietz, M.G., et al. Zinc finger domains and phorbol ester pharmacophore: analysis of binding to mutated form of protein kinase C z and the vav and c-raf proto-oncogene products. J. Biol. Chem. 269 (1994), 11590–11594.
10. Pu, Y., et al. Effects on ligand interaction and membrane translocation of the positively charged arginine residues situated along the C1 domain binding cleft in the atypical protein kinase C isoforms. J. Biol. Chem. 281:44 (2006), 33773–33788.
11. Lamark, T., et al. Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. J. Biol. Chem. 278:36 (2003), 34568–34581.
12. Gould, C.M., et al. The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. J. Biol. Chem. 284:8 (2009), 4921–4935.
13. Guertin, D.A., et al. Ablation in mice of the mTORC components raptor: rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11:6 (2006), 859–871.
14. Behn-Krappa, A., Newton, A.C., The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr. Biol. 9:14 (1999), 728–737.
15. Tobias, I.S., et al. Protein kinase Czeta exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation. Biochem. J. 473:4 (2016), 509–523.
16. Facchinetti, V., et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27:14 (2008), 1932–1943.
17. Leonard, T.A., et al. Crystal structure and allosteric activation of protein kinase C betaII. Cell 144:1 (2011), 55–66.
18. Antal, C.E., et al. Intramolecular C2 domain-mediated autoinhibition of protein kinase C betaII. Cell Rep. 12:8 (2015), 1252–1260.
19. Corbalan-Garcia, S., et al. A new phosphatidylinositol 4,5-bisphosphate-binding site located in the C2 domain of protein kinase Calpha. J. Biol. Chem. 278:7 (2003), 4972–4980.
20. Evans, J.H., et al. Specific translocation of protein kinase Calpha to the plasma membrane requires both Ca2+ and PIP2 recognition by its C2 domain. Mol. Biol. Cell 17:1 (2006), 56–66.
21. Nakanishi, H., Exton, J.H., Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J. Biol. Chem. 267:23 (1992), 16347–16354.
22. Graybill, C., et al. Partitioning-defective protein 6 (Par-6) activates atypical protein kinase C (aPKC) by pseudosubstrate displacement. J. Biol. Chem. 287:25 (2012), 21003–21011.
23. Tsai, L.C., et al. Zeta inhibitory peptide disrupts electrostatic interactions that maintain atypical protein kinase C in its active conformation on the scaffold p62. J. Biol. Chem. 290:36 (2015), 21845–21856.
24. Tobias, I.S., Newton, A.C., Protein Scaffolds control localized protein kinase czeta activity. J. Biol. Chem. 291:26 (2016), 13809–13822.
25. Soriano, E.V., et al. aPKC inhibition by par3 CR3 flanking regions controls substrate access and underpins apical-junctional polarization. Dev. Cell 38:4 (2016), 384–398.
26. Gallegos, L.L., Kunkel, M.T., Newton, A.C., Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J. Biol. Chem. 281 (2006), 30947–30956.
27. Antal, C.E., Newton, A.C., Spatiotemporal dynamics of phosphorylation in lipid second messenger signaling. Mol. Cell Proteomics 12:12 (2013), 3498–3508.
28. Jaken, S., Tashjian, A.H. Jr., Blumberg, P.M., Characterization of phorbol ester receptors and their down-modulation in GH4C1 rat pituitary cells. Cancer Res. 41:6 (1981), 2175–2181.
29. Dutil, E.M., et al. In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation. J. Biol. Chem. 269:47 (1994), 29359–29362.
30. Gao, T., Furnari, F., Newton, A.C., pH LPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18:1 (2005), 13–24.
31. Gao, T., Brognard, J., Newton, A.C., The phosphatase pH LPP controls the cellular levels of protein kinase C. J. Biol. Chem. 283:10 (2008), 6300–6311.
32. Hansra, G., et al. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes [In Process Citation]. Biochem. J 342:Pt. 2 (1999), 337–344.
33. Leontieva, O.V., Black, J.D., Identification of two distinct pathways of protein kinase Calpha down-regulation in intestinal epithelial cells. J. Biol. Chem. 279:7 (2004), 5788–5801.
34. Goode, N.T., Hajibagheri, M.A.N., Parker, P.J., Protein kinase C (PKC)-induced PKC down-regulation. J. Biol. Chem. 270 (1995), 2669–2673.
35. Abrahamsen, H., et al. Peptidyl-prolyl isomerase pin1 controls down-regulation of conventional protein kinase C isozymes. J. Biol. Chem. 287:16 (2012), 13262–13278.
36. Hecker, E., Cocarcinogenic principles from the seed oil of Croton tiglium and from other Euphorbiaceae. Cancer Res. 28:11 (1968), 2338–2349.
37. Berenblum, I., Shubik, P., The role of croton oil applications, associated with a single painting of a carcinogen, in tumour induction of the mouse's skin. Br. J. Cancer 1:4 (1947), 379–382.
38. Griner, E.M., Kazanietz, M.G., Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 7:4 (2007), 281–294.
39. Weber, J., Hecker, E., Cocarcinogens of the diterpene ester type from Croton flavens L. and esophageal cancer in Curacao. Experientia 34:6 (1978), 679–682.
40. Hecker, E., et al. The chemical structure of a cocarcinogen and of phorbol isolated from croton oil. J. Med. Chem. 9:2 (1966), 246–247.
41. Hecker, E., Co-carcinogens or modulators of carcinogenesis: new aspects of the etiology of human tumors and of the molecular mechanisms of carcinogenesis. Naturwissenschaften 65:12 (1978), 640–648.
42. Driedger, P.E., Blumberg, P.M., Specific binding of phorbol ester tumor promoters. Proc. Natl. Acad. Sci. U. S. A. 77 (1980), 567–571.
43. Blumberg, P.M., et al. Mechanism of action of the phorbol ester tumor promoters: specific receptors for lipophilic ligands. Biochem. Pharmacol. 33:6 (1984), 933–940.
44. Castagna, M., et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257 (1982), 7847–7851.
45. Zhang, L.L., et al. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin. Transl. Oncol. 17:5 (2015), 371–377.
46. de Vries, D.J., et al. Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain. Biochem. Pharmacol. 37:21 (1988), 4069–4073.
47. Marshall, J.L., et al. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies. Cancer Biol. Ther. 1:4 (2002), 409–416.
48. Prevostel, C., et al. The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene 11:4 (1995), 669–674.
49. Prevostel, C., et al. Protein kinase C(alpha) actively downregulates through caveolae- dependent traffic to an endosomal compartment. J. Cell Sci. 113:Pt. 14 (2000), 2575–2584.
50. Vallentin, A., Lo, T.C., Joubert, D., A single point mutation in the V3 region affects protein kinase Calpha targeting and accumulation at cell–cell contacts. Mol. Cell. Biol. 21:10 (2001), 3351–3363.
51. Gao, J., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6(269), 2013, pl1.
52. Antal, C.E., et al. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell 160:3 (2015), 489–502.
53. McSkimming, D.I., et al. KinView: a visual comparative sequence analysis tool for integrated kinome research. Mol. Biosyst. 12:12 (2016), 3651–3665.
54. Creixell, P., et al. Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. Cell 163:1 (2015), 202–217.
55. Stransky, N., et al. The landscape of kinase fusions in cancer. Nat. Commun., 5, 2014, 4846.
56. Knauf, J.A., et al. Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. J. Biol. Chem. 274:33 (1999), 23414–23425.
57. Garcia-Paramio, P., et al. The broad specificity of dominant inhibitory protein kinase C mutants infers a common step in phosphorylation. Biochem. J. 333:Pt. 3 (1998), 631–636.
58. Hein, M.Y., et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 163:3 (2015), 712–723.
59. Meharena, H.S., et al. Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol., 11(10), 2013, e1001680.
60. Hunter, T., Ling, N., Cooper, J.A., Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature 311 (1984), 480–483.
61. Hunter, T., Ling, N., Cooper, J.A., Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature 311:5985 (1984), 480–483.
62. Livneh, E., et al. Release of a phorbol ester-induced mitogenic block by mutation at Thr-654 of the epidermal growth factor receptor. Mol. Cell. Biol. 8:6 (1988), 2302–2308.
63. Livneh, E., et al. An insertional mutant of epidermal growth factor receptor allows dissection of diverse receptor functions. EMBO J. 6:9 (1987), 2669–2676.
64. Santiskulvong, C., Rozengurt, E., Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by Gq-coupled receptor agonists. Cell Signal. 19:6 (2007), 1348–1357.
65. Ouyang, X., Gulliford, T., Epstein, R.J., The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signalling. Carcinogenesis 19:11 (1998), 2013–2019.
66. Pitcher, J., et al. Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase: cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry 31:12 (1992), 3193–3197.
67. Hosey, M.M., et al. Multiple mechanisms involving protein phosphorylation are linked to desensitization of muscarinic receptors. Life Sci. 56:11–12 (1995), 951–955.
68. Namkung, Y., Sibley, D.R., Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. J. Biol. Chem. 279:47 (2004), 49533–49541.
69. Fujimoto, K., et al. Identification of protein kinase C phosphorylation sites involved in phorbol ester-induced desensitization of the histamine H1 receptor. Mol. Pharmacol. 55:4 (1999), 735–742.
70. Sipeki, S., et al. PKCalpha reduces the lipid kinase activity of the p110alpha/p85alpha PI3K through the phosphorylation of the catalytic subunit. Biochem. Biophys. Res. Commun. 339:1 (2006), 122–125.
71. Tanaka, Y., et al. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J. Biol. Chem. 278:36 (2003), 33753–33762.
72. Bivona, T.G., et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 21:4 (2006), 481–493.
73. Barcelo, C., et al. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res. 74:4 (2014), 1190–1199.
74. Wang, M.T., et al. K-Ras promotes tumorigenicity through suppression of non-canonical wnt signaling. Cell 163:5 (2015), 1237–1251.
75. Szallasi, Z., Blumberg, P.M., Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. Cancer Res., 1991, 5355–5360.
76. Belot, A., et al. Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 65:8 (2013), 2161–2171.
77. Kuehn, H.S., et al. Loss-of-function of the protein kinase C delta (PKCdelta) causes a B-cell lymphoproliferative syndrome in humans. Blood 121:16 (2013), 3117–3125.
78. Salzer, E., et al. B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C delta. Blood 121:16 (2013), 3112–3116.
79. Kiykim, A., et al. Potentially beneficial effect of hydroxychloroquine in a patient with a novel mutation in protein kinase cdelta deficiency. J. Clin. Immunol. 35:6 (2015), 523–526.
80. Bernatsky, S., et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 52:5 (2005), 1481–1490.
81. Salzer, E., et al. Protein kinase C delta: a gatekeeper of immune homeostasis. J. Clin. Immunol. 36:7 (2016), 631–640.
82. Payne, S.R., Kemp, C.J., Tumor suppressor genetics. Carcinogenesis 26:12 (2005), 2031–2045.
83. Eng, C., PTEN: one gene, many syndromes. Hum. Mutat. 22:3 (2003), 183–198.
84. Hollander, M.C., Blumenthal, G.M., Dennis, P.A., PTEN loss in the continuum of common cancers: rare syndromes and mouse models. Nat. Rev. Cancer 11:4 (2011), 289–301.
85. Sanchez-Cespedes, M., A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 26:57 (2007), 7825–7832.
86. Alfonso, S.I.et al., Gain-of-function mutations in protein kinase Calpha (PKCalpha) may promote synaptic defects in Alzheimer's disease. Sci. Signal., 9(427), 2016, ra47.
87. Tagawa, K., et al. Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. Hum. Mol. Genet. 24:2 (2015), 540–558.
88. Kubo, M., et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat. Genet. 39:2 (2007), 212–217.
89. Takata, Y., et al. Genetic association between the PRKCH gene encoding protein kinase Ceta isozyme and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 56:1 (2007), 30–42.
90. Goto, Y., et al. PRKCH gene polymorphism is associated with the risk of severe gastric atrophy. Gastric Cancer 13:2 (2010), 90–94.
91. Zurgil, U., et al. PKCeta promotes senescence induced by oxidative stress and chemotherapy. Cell. Death. Dis., 5, 2014, e1531.
92. Pongracz, J., et al. Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int. J. Cancer 61:1 (1995), 35–39.
93. Craven, P.A., DeRubertis, F.R., Loss of protein kinase C delta isozyme immunoreactivity in human adenocarcinomas. Dig. Dis. Sci. 39:3 (1994), 481–489.
94. Suga, K., et al. Down-regulation of protein kinase C-alpha detected in human colorectal cancer. Biochem. Mol. Biol. Int. 44:3 (1998), 523–528.
95. Dowling, C.M., et al. Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival. Oncotarget, 2016.
96. Lu, H.C., et al. Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. Pathology (Phila.) 41:7 (2009), 626–629.
97. Reno, E.M., et al. Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum. Pathol. 39:1 (2008), 21–29.
98. Mandil, R., et al. Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. 61:11 (2001), 4612–4619.
99. Myhre, S., et al. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol. Oncol. 7:3 (2013), 704–718.
100. Kataoka, K., et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47:11 (2015), 1304–1315.
101. Basu, A., Pal, D., Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death. Sci. World J. 10 (2010), 2272–2284.
102. Mauro, L.V., et al. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer. Pancreas 39:1 (2010), e31–41.
103. Symonds, J.M., et al. Protein kinase C delta is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 71:6 (2011), 2087–2097.
104. Hafeez, B.B., et al. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res. 71:6 (2011), 2318–2327.
105. Garg, R., et al. Protein kinase C and cancer: what we know and what we do not. Oncogene 33:45 (2014), 5225–5237.
106. Allen-Petersen, B.L., et al. Protein kinase Cdelta is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene 33:10 (2014), 1306–1315.
107. McKiernan, E., et al. Protein kinase Cdelta expression in breast cancer as measured by real-time PCR: western blotting and ELISA. Br. J. Cancer 99:10 (2008), 1644–1650.
108. Gyorffy, B., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123:3 (2010), 725–731.
109. Galvez, A.S., et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol. Cell. Biol. 29:1 (2009), 104–115.
110. Linch, M., et al. A cancer-associated mutation in atypical protein kinase Ciota occurs in a substrate-specific recruitment motif. Sci. Signal., 6(293), 2013, ra82.
111. Ma, L., et al. Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis. Cell 152:3 (2013), 599–611.
112. Llado, V., et al. Repression of intestinal stem cell function and tumorigenesis through direct phosphorylation of beta-catenin and yap by PKCzeta. Cell Rep., 2015.
113. Nakanishi, Y., et al. Control of paneth cell fate: intestinal inflammation, and tumorigenesis by PKClambda/iota. Cell Rep. 16:12 (2016), 3297–3310.
114. Parker, P.J., et al. Atypical protein kinase Ciota as a human oncogene and therapeutic target. Biochem. Pharmacol. 88:1 (2014), 1–11.
115. Ali, S.A., et al. Protein kinase ciota drives a NOTCH3-dependent stem-like phenotype in mutant KRAS lung adenocarcinoma. Cancer Cell 29:3 (2016), 367–378.
116. Justilien, V., et al. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25:2 (2014), 139–151.
117. Kusne, Y., et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. Sci. Signal., 7(338), 2014, ra75.
118. Saxon, M.L., Zhao, X., Black, J.D., Activation of protein kinase C isozymes is associated with post-mitotic events in intestinal epithelial cells in situ. J. Cell Biol. 126:3 (1994), 747–763.
119. Frey, M.R., et al. Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J. Biol. Chem. 272:14 (1997), 9424–9435.
120. Oster, H., Leitges, M., Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice. Cancer Res. 66:14 (2006), 6955–6963.
121. Hill, K.S., et al. Protein kinase Calpha suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFbeta signaling axis. Oncogene 33:16 (2014), 2134–2144.
122. Kim, J.Y., et al. c-Myc phosphorylation by PKCzeta represses prostate tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 110:16 (2013), 6418–6423.
123. Kazanietz, M.G., Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol. Carcinog. 28:1 (2000), 5–11.
124. Schrott, L.M., et al. Acute oral Bryostatin-1 administration improves learning deficits in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 12:1 (2015), 22–31.
125. Don, A.S., Zheng, X.F., Recent clinical trials of mTOR-targeted cancer therapies. Rev. Recent Clin. Trials 6:1 (2011), 24–35.
126. Neckers, L., Workman, P., Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res. 18:1 (2012), 64–76.